Key facts
- Béa Fertility’s last known valuation is $28.8M (May 2025).
- It has raised $7.0M; the latest was Later Stage VC ($2.9M) in May 2025.
- Notable investors include Octopus Ventures, 7percent Ventures, Molten Ventures, Spacestation (UK), Calm/Storm Ventures — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Béa Fertility
- ·The full record, as it builds
Funding rounds
No funding rounds for Béa Fertility are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Béa Fertility
Developer of fertility therapy devices designed to provide clinical-standard treatment at home. The company's product contains ovulation assessments, insemination units, pregnant assessments, semen pattern assortment pots, and access to an application to assist in observing ovulation dates, enabling customers to access affordable fertility treatment in the comfort of their homes.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2020
- Employees
- 9
- Website
- beafertility.com/
- Ownership
- Privately Held (backing)
Béa Fertility doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Béa Fertility shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Béa Fertility in its N-PORT filings yet. We sweep new filings monthly.